| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 780 | 310 | 90 | 10 | 20 |
| Sales Growth | +151.61% | +244.44% | +800.01% | -50.00% | unch |
| Net Income | -35,320 | -30,270 | -26,810 | -20,350 | -16,100 |
| Net Income Growth | -16.68% | -12.91% | -31.74% | -26.40% | +10.61% |
Volitionrx Ltd (VNRX)
0.5611 x 1 0.5800 x 2
Post-market by (Cboe BZX)
0.5611 -0.0209 (-3.59%) 03/14/25 [NYSE Arca]
0.5611 x 1 0.5800 x 2
Post-market 0.5611 unch (unch) 20:00 ET
for Fri, Mar 14th, 2025
Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company's development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.
Fiscal Year End Date: 12/31